Genmab A/S (NASDAQ:GMAB) Short Interest Down 11.4% in November

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 2,020,000 shares, a decline of 11.4% from the November 15th total of 2,280,000 shares. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is presently 1.8 days. Approximately 0.3% of the shares of the stock are short sold.

Hedge Funds Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the company. DDD Partners LLC purchased a new position in Genmab A/S during the 2nd quarter valued at about $8,860,000. Two Sigma Advisers LP increased its position in Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after purchasing an additional 280,900 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock valued at $7,000,000 after buying an additional 145,689 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after acquiring an additional 103,859 shares during the period. Finally, Sanctuary Advisors LLC bought a new position in shares of Genmab A/S in the 2nd quarter worth approximately $1,354,000. 7.07% of the stock is owned by institutional investors.

Genmab A/S Stock Performance

GMAB stock traded up $0.01 during trading on Tuesday, hitting $20.03. 1,075,716 shares of the company traded hands, compared to its average volume of 741,872. The company has a 50-day moving average of $22.08 and a 200-day moving average of $24.99. The firm has a market capitalization of $13.26 billion, a PE ratio of 19.49, a P/E/G ratio of 0.67 and a beta of 0.96. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $32.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The firm had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the prior year, the business posted $0.47 EPS. Sell-side analysts expect that Genmab A/S will post 1.28 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on GMAB shares. Morgan Stanley reiterated an "equal weight" rating and issued a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Redburn Atlantic assumed coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating for the company. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and an average price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.